Incyte (NASDAQ:INCY) Issues Quarterly Earnings Results

Incyte (NASDAQ:INCY) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping the consensus estimate of ($3.93) by $0.33, FiscalAI reports. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The business had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter in the previous year, the firm posted $2.26 earnings per share. The company’s quarterly revenue was up 14.0% compared to the same quarter last year.

Here are the key takeaways from Incyte’s conference call:

• Strong quarterly performance and raised guidance: Third-quarter revenue and net sales both increased 14% year over year to $1.56 billion and $1.32 billion, respectively. Incyte raised full-year 2026 net sales guidance to $5.21 billion–$5.30 billion, driven by OPZELURA and hematology/oncology products.
• OPZELURA continued to drive growth: OPZELURA sales rose 36% to $255 million, with underlying U.S. demand up 24% on a pro forma basis and strong new-patient growth. European approval for moderate atopic dermatitis and potential additional HS applications could further expand the franchise.
• Late-stage pipeline advanced across multiple therapeutic areas: Incyte highlighted encouraging early data for its G12D inhibitor in pancreatic and colorectal cancer and its TGF?R2×PD-1 bispecific in colorectal cancer. The company now has six Phase III programs and expects additional data and regulatory milestones over the next 12–18 months.
• CALR-directed MPN program remains a major value driver: Management expects to present more mature frontline data for INCA033989 at ASH and plans to advance a potentially more potent, longer-acting next-generation CALR antibody into the clinic in early 2027. The company is also discussing alternative composite endpoints with the FDA that could better capture disease modification.
• Pipeline investment and portfolio pruning create near-term risks: GAAP operating expenses surged 146%, largely due to the $1.23 billion Vega acquisition-related R&D charge, while the company discontinued enrollment in the Phase III platinum-resistant ovarian cancer study for its CDK2 inhibitor. Jakafi sales grew only 4% because of pricing effects, and management continues to prepare for retaining only 10%–30% of the franchise by 2029.

Incyte Stock Down 0.1%

Incyte stock traded down $0.07 during midday trading on Thursday, reaching $116.80. The company’s stock had a trading volume of 3,043,818 shares, compared to its average volume of 1,733,634. Incyte has a fifty-two week low of $89.25 and a fifty-two week high of $132.60. The company has a market cap of $23.68 billion, a P/E ratio of 14.88, a P/E/G ratio of 4.79 and a beta of 0.74. The business has a 50-day simple moving average of $120.86 and a 200-day simple moving average of $108.02.

Insider Transactions at Incyte

In other news, insider Pablo J. Cagnoni sold 2,642 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $112.71, for a total transaction of $297,779.82. Following the sale, the insider owned 183,200 shares of the company’s stock, valued at approximately $20,648,472. This trade represents a 1.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick A. Mayes sold 41,899 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $119.46, for a total value of $5,005,254.54. Following the sale, the executive vice president directly owned 61,441 shares in the company, valued at $7,339,741.86. This trade represents a 40.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 55,342 shares of company stock valued at $6,659,208 over the last ninety days. 16.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

INCY has been the subject of a number of recent research reports. Morgan Stanley started coverage on Incyte in a report on Tuesday, October 20th. They issued an “equal weight” rating and a $119.00 target price for the company. Piper Sandler upped their price target on Incyte from $110.00 to $130.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Leerink Partners increased their price target on Incyte from $131.00 to $155.00 and gave the company an “outperform” rating in a research report on Monday, August 3rd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $104.00 price objective on shares of Incyte in a research note on Thursday, August 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Incyte in a research report on Tuesday. Twelve research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $131.43.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $1.56 billion, exceeding the $1.46 billion consensus estimate. The adjusted loss of $3.60 per share was also narrower than analysts expected, helped by solid product performance. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
• Positive Sentiment: Incyte raised its 2026 total net-sales guidance to $5.21 billion-$5.30 billion from $5.13 billion-$5.26 billion previously. Opzelura sales increased 36% to $255 million, while Hematology and Oncology portfolio sales grew 38% to $235 million; Jakafi and Jakafi XR sales rose 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
• Positive Sentiment: A Phase 1 study began dosing its first patient with Adagene’s muzastotug in combination with Incyte’s INCA33890 for microsatellite-stable colorectal cancer, providing a development catalyst for Incyte’s pipeline. Adagene Announces Dosing of First Patient
• Neutral Sentiment: Management’s earnings commentary highlighted continued commercial momentum and pipeline progress, including early interest in its G12D pancreatic-cancer program, but these programs remain development-stage opportunities. Incyte Q3 2026 Earnings Call Transcript
• Negative Sentiment: Incyte reported a GAAP net loss of approximately $785 million, or $3.86 per share, largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The acquisition-related expense obscures otherwise stronger operating results and may weigh on sentiment. Incyte Posts Loss in Q3, But Revenue Rises
• Negative Sentiment: Although guidance was raised, one analysis characterized the full-year sales outlook as materially below expectations, creating a potential “raise but disappoint” reaction. Reported insider activity also showed selling without purchases over the past six months. Incyte’s Q3 2026 Sales Beat Estimates

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.